Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Non-Current Liabilities (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Total Non-Current Liabilities over the past 12 years, most recently at $157.2 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $157.2 million for Q4 2025, up 122.18% from a year ago — trailing twelve months through Dec 2025 was $157.2 million (up 122.18% YoY), and the annual figure for FY2025 was $157.2 million, up 122.18%.
  • Total Non-Current Liabilities for Q4 2025 was $157.2 million at Viridian Therapeutics, Inc.\DE, up from $71.6 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for VRDN hit a ceiling of $157.2 million in Q4 2025 and a floor of $14.3 million in Q3 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $41.4 million (2022), compared with a mean of $46.0 million.
  • Peak annual rise in Total Non-Current Liabilities hit 162.8% in 2022, while the deepest fall reached 7.96% in 2022.
  • Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities stood at $14.8 million in 2021, then surged by 162.8% to $38.9 million in 2022, then rose by 22.03% to $47.4 million in 2023, then surged by 49.25% to $70.8 million in 2024, then surged by 122.18% to $157.2 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $157.2 million (Q4 2025), $71.6 million (Q3 2025), and $65.1 million (Q2 2025) per Business Quant data.